← SynDRA
GANAXOLONE
SynDRA canonical compound SYN0025580 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | GABRA1 | GABRA2 | GABRA3 | GABRA4 | GABRA5 | GABRA6 |
|---|
| Mechanism of action | GABA receptor modulator |
|---|
All known targets
- GABRA1
- GABRA2
- GABRA3
- GABRA4
- GABRA5
- GABRA6
- GABRB1
- GABRG2
- GABRB2
- GABRB3
- GABRD
- GABRE
Mechanisms of action (all sources)
- GABRA1 POSITIVE ALLOSTERIC MODULATOR
- GABRB2 POSITIVE ALLOSTERIC MODULATOR
- GABRG2 POSITIVE ALLOSTERIC MODULATOR
- GABRB3 POSITIVE ALLOSTERIC MODULATOR
- GABRA4 POSITIVE ALLOSTERIC MODULATOR
- GABRG3 POSITIVE ALLOSTERIC MODULATOR
- GABRQ POSITIVE ALLOSTERIC MODULATOR
- GABRA3 POSITIVE ALLOSTERIC MODULATOR
- GABRP POSITIVE ALLOSTERIC MODULATOR
- GABRD POSITIVE ALLOSTERIC MODULATOR
- GABRG1 POSITIVE ALLOSTERIC MODULATOR
- GABRB1 POSITIVE ALLOSTERIC MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- APEX1
- ARSA
- DRD1
- EHMT2
- HDAC6
- KAT2A
- NFE2L2
- VDR
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ANDR
- CP2D6
- CP3A7
- ESR2
- GABRB2
- GABRB3
- GABRD
- GABRE
- GABRG1
- GABRG3
- GABRP
- GABRQ
Drug classes
- GABA Agents
- GABA Modulators
- Neurosteroids
- Neurotransmitter Agents
- GABA A Receptor Positive Modulators
- Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
ATC classes
Cross-references
Synonyms
- ZTALMY
- Ztalmy
- ztalmy
- GNX
- CCD 1042
- Ganaxolona
- CCD-1042
- CCD1042
- DEA NO. 2401
- Ganaxolone [USAN]
- Ganaxolone (USAN/INN)
- 3alpha-Hydroxy-3-methyl-5alpha-pregnan-20-one
- 3alpha-Hydroxy-3beta-methyl-5alpha-pregnan-20-one
- ganaxolona
- DTXCID4026503
- ganaxolonum
- RefChem:57127
- C22H36O2
- NCGC00165802-02
- CAS-38398-32-2
- Ganaxolone [USAN:INN]
- UNII-98WI44OHIQ
- Ganaxolone, solid
- Ztalmy (TN)
- GANAXOLONE [MI]
- GANAXOLONE [INN]
- GANAXOLONE [WHO-DD]
- SCHEMBL144522
- GTPL11942
- CHEBI:177658
- PGTVWKLGGCQMBR-FLBATMFCSA-N
- HMS3261K19
- Tox21_112264
- Tox21_500379
- BDBM50369240
- MFCD09971088
- AKOS027327586
- Tox21_112264_1
Reported adverse events
- Pyrexia
- Sedation
- Somnolence
- Bronchitis
- Gait disturbance
- Influenza
- Nasal congestion
- Upper respiratory tract infection
- Seasonal allergy
Look up GANAXOLONE in the interactive SynDRA portal →